Skip to main content
Erschienen in: Clinical Journal of Gastroenterology 4/2018

01.03.2018 | Case Report

Five-year postsurgical monitoring of serum p53 antibody for locally advanced esophageal squamous cell carcinoma

verfasst von: Ryosuke Kochi, Satoshi Yajima, Tatsuki Nanami, Takashi Suzuki, Yoko Oshima, Natsuki Tokura, Jun Takatsuka, Kimihiko Funahashi, Naobumi Tochigi, Hideaki Shimada

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Serum p53 antibody (s-p53-Ab) titers were postoperatively monitored for over 5 years in a 67-year-old man with locally advanced esophageal squamous cell carcinoma. The tumor stage was classified as clinical stage II (cT3N0M0). Serum SCC antigen (s-SCC-Ag; 6.2 ng/mL) and s-p53-Ab (3.83 U/mL) were noted to be positive before surgery. Radical esophagectomy with three-field lymph node dissection was performed without neoadjuvant therapy. Pathological findings of the surgically resected specimens revealed a stage II tumor (pT3N0M0). Postoperatively, the patients did not receive any adjuvant therapy. Although the s-SCC-Ag was found to be negative at 2 months postoperatively, s-SCC-Ag was found to be six times positive despite no signs of recurrence. The s-p53-Ab titers constantly decreased to less than the cutoff value at 6 months postoperatively and continuously decreased over 5 years postoperatively. Finally, s-p53-Ab titers became less than the detection limit value at 60 months postoperatively. No recurrence was observed throughout the postoperative course. This case report is the first to describe the five-year monitoring of postoperative changes in s-p53-Ab titers in a patient with locally advanced esophageal squamous cell carcinoma without recurrence. s-p53-Ab titers seemed to be more useful than s-SCC-Ag for disease monitoring in this case.
Literatur
1.
Zurück zum Zitat Shimada H, Yajima S, Oshima Y, et al. Impact of serum biomarkers on esophageal squamous cell carcinoma. Esophagus. 2014;9:131–40.CrossRef Shimada H, Yajima S, Oshima Y, et al. Impact of serum biomarkers on esophageal squamous cell carcinoma. Esophagus. 2014;9:131–40.CrossRef
2.
Zurück zum Zitat Shimada H, Shiratori T, Takeda A, et al. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 2009;33:272–7.CrossRefPubMed Shimada H, Shiratori T, Takeda A, et al. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 2009;33:272–7.CrossRefPubMed
3.
Zurück zum Zitat Saito F, Shimada H, Ogata H, et al. Detection of the early phase of esophageal cancer progression into lamina propria mucosae by the serum p53 antibody. Esophagus. 2017;1:1–4. Saito F, Shimada H, Ogata H, et al. Detection of the early phase of esophageal cancer progression into lamina propria mucosae by the serum p53 antibody. Esophagus. 2017;1:1–4.
4.
Zurück zum Zitat Yamashita K, Makino T, Tanaka K, et al. Peritherapeutic serum p53 antibody titers are predictors of survival in patients with esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy and surgery. World J Surg. 2017;41:1566–74.CrossRefPubMed Yamashita K, Makino T, Tanaka K, et al. Peritherapeutic serum p53 antibody titers are predictors of survival in patients with esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy and surgery. World J Surg. 2017;41:1566–74.CrossRefPubMed
5.
Zurück zum Zitat Hiyoshi Y, Yoshida N, Watanabe M, et al. The presence of serum p53 antibody predicts the pathological tumor response to neoadjuvant chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) in esophageal squamous cell carcinoma. World J Surg. 2017;41:480–6.CrossRefPubMed Hiyoshi Y, Yoshida N, Watanabe M, et al. The presence of serum p53 antibody predicts the pathological tumor response to neoadjuvant chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) in esophageal squamous cell carcinoma. World J Surg. 2017;41:480–6.CrossRefPubMed
6.
Zurück zum Zitat Shimada H, Nagata M, Cho A, et al. Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case. Surg Today. 2014;44:1957–61.CrossRefPubMed Shimada H, Nagata M, Cho A, et al. Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case. Surg Today. 2014;44:1957–61.CrossRefPubMed
7.
Zurück zum Zitat Murayama K, Nanami T, Suzuki T, et al. Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery. Clin J Gastroenterol. 2017;24:1–4. Murayama K, Nanami T, Suzuki T, et al. Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery. Clin J Gastroenterol. 2017;24:1–4.
8.
Zurück zum Zitat Kubota Y, Shimada H, Magoshi S, et al. Serum p53 antibody is a useful biomarker for long-term monitoring of breast cancer: report of a recurrent case after surgery. Toho J Med. 2016;2:22–5. Kubota Y, Shimada H, Magoshi S, et al. Serum p53 antibody is a useful biomarker for long-term monitoring of breast cancer: report of a recurrent case after surgery. Toho J Med. 2016;2:22–5.
9.
Zurück zum Zitat Shimada H, Ochiai T, Nomura F, et al. Titration of serum p53 antibodies in 1,085 patient with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.CrossRefPubMed Shimada H, Ochiai T, Nomura F, et al. Titration of serum p53 antibodies in 1,085 patient with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.CrossRefPubMed
10.
Zurück zum Zitat Shimada H, Takeda A, Arima M, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677–83.CrossRefPubMed Shimada H, Takeda A, Arima M, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677–83.CrossRefPubMed
Metadaten
Titel
Five-year postsurgical monitoring of serum p53 antibody for locally advanced esophageal squamous cell carcinoma
verfasst von
Ryosuke Kochi
Satoshi Yajima
Tatsuki Nanami
Takashi Suzuki
Yoko Oshima
Natsuki Tokura
Jun Takatsuka
Kimihiko Funahashi
Naobumi Tochigi
Hideaki Shimada
Publikationsdatum
01.03.2018
Verlag
Springer Japan
Erschienen in
Clinical Journal of Gastroenterology / Ausgabe 4/2018
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-018-0839-3

Weitere Artikel der Ausgabe 4/2018

Clinical Journal of Gastroenterology 4/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.